Metabolic syndrome (MS) is a multicomponent common cardiovascular risk factor. Along with dyslipidemia, iron deficiency against the background of intestinal dysbiosis is considered as one of the latent components of MS. The effect of Synthesit iron citrate in multiple organ MS on its metabolic pool was studied. Normalization of iron and ferritin levels, blood lipids, lipid peroxidation (LP) indicators, antioxidant system (AOS) enzymes, mitochondrial peptides and rheological blood values were noted against the background of Synthesit iron citrate long-term administration.

OBJECTIVE

To study the metabolic pool condition in multiple organ MS and to evaluate the role of Synthesit iron citrate in its correction at pre-pharmacological stage.

MATERIAL AND METHODS

The study included 68 patients with MS. Participants were divided into 2 groups: the 1st group — 12 patients with MS without iron deficiency, the 2nd group — 56 patients with MS and iron deficiency. All subjects were examined according to clinical recommendations and standards of medical care. The main metabolic indicators were studied over time using established methods. The correction protocol included orally administered Synthesit iron citrate.

RESULTS

Patients with multiple organ MS and iron deficiency with pronounced dyslipidemia had increased LP indicators, inhibition of AOS enzymes with mitochondrial dysfunction against the background of hypoferritinemia, hypotransferrinemia and hyperrheological syndrome. The conducted long-term (within 30 days) pre-pharmacological treatment with biologically active nutraceutic Synthesit iron citrate has led to normalization of the analyzed indicators. The obtained data suggest to consider Synthesit iron citrate as an adjuvant targeted biologically active nutraceutic at pre-pharmacological stage of metabolic disorders correction.

CONCLUSION

In metabolic syndrome multiple organ disorders should be considered with regard to mitochondrial organ dysfunction due to intestinal dysbiosis and metabolic-associated fatty liver disease. These conditions are accompanied by iron deficiency, hyperperoxidation, antioxidant deficiency, dyslipidemia, hemorheological and microcirculatory transcapillary disorders. The administration of long-term adjuvant targeted preventive therapy with Synthesit iron citrate can be used as a pre-pharmacological correction.